ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1125

Genomics of JAK-STAT Signaling in Venous Thromboembolism

Stine R Haysen, Ane Langkilde-Lauesen Nielsen, Per Qvist and Tue Kragstrup, Aarhus University, Aarhus, Denmark

Meeting: ACR Convergence 2022

Keywords: Bioinformatics, Disease-Modifying Antirheumatic Drugs (Dmards), Genomics and Proteomics

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Genetics, Genomics and Proteomics Poster

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Janus kinase inhibitors (JAKi) have been associated with an increased risk of venous thromboembolism (VTE). This concern limits the use of JAKi-based therapy. Hence, to improve risk stratification and drug development, it is crucial to understand the possible implication of dysregulated JAK-signal transducers and activators of transcription (STAT) signaling in the pathogenesis of VTE. The objective of this study is to clarify the putative genomic vulnerability to dysregulated JAK-STAT signaling in VTE.

Methods: Here, we systematically mine and analyze large-scale genomic datasets generated from studies comparing VTE patients with healthy controls. First, datasets were divided into 1) single-nucleotide polymorphisms (SNPs) from genome wide associated studies (GWAS), 2) differentially expressed genes (DEGs) from RNAseq and microarrays, and 3) differentially abundant proteins (DAPs) from mass spec proteomics. Then, JAK-STAT pathway genes were defined by Kyoto Encyclopedia of Genes and Genomes (KEGG hsa04630) and available STAT family (STAT1-3) transcription factor binding sites (TFBS) were extracted from the JASPAR database. Finally, Chi-squared test was used to evaluate the representation of genes encoding the JAK-STAT pathway (KEGG) and STAT family TFBS (JASPAR) and their association to VTE (GWAS, DEGs and DAPs). The two bioinformatic tools MAGMA and Ciiider were used to validate the cumulative gene set association, genetic risk burden and molecular characteristics related to JAK-STAT signaling in VTE.

Results: We do not observe a significant overrepresentation of JAK-STAT genes (ntotal=162) among genes annotated to VTE significant GWA loci (ntotal=147, p=0.48). Similarly, the JAK-STAT gene set show no cumulative association to VTE (p=0.98). Applying the same gene set association approach to the STAT target gene sets (ntotal=4570) does not reveal significant association between VTE and STAT1 (noverlap=10, p=0.47), STAT1:STAT2 heterodimer (noverlap=18, p=0.17) and STAT3 (noverlap=6, p=0.20) target gene sets. At the functional molecular level, we do not see any significant overlap between molecules acting in the JAK-STAT pathway and DEGs (ntotal=507, p=0.06) or differentially abundant proteins (DAPs; ntotal=35, p=0.57). However, we observe a significant overlap between downregulated DEGs (ntotal=362) and the STAT1:STAT2 heterodimer target gene set (ntotal= 2155, noverlap=48, p< 0.0001) including downregulation of IL-27RA and CCND3 (Figure 1). Supporting the biological relevance of this finding, we find a weak but statistically significant enrichment of STAT1 TFBS motifs in the promotor sequence of downregulated DEGs compared to non-DEGs (p=0.02).

Conclusion: Here, we provide a coherent approach to assess the genomic basis for the reported association between JAKi treatment and VTE. Our preliminary data suggest that genes under transcriptional control of STAT family TFs may be dysregulated in VTE patients. Obviously, genomic data mining alone cannot guide medical decision making concerning the use of JAKi. However, our results provide a basis for further investigation of adverse events seen with JAKi.

Supporting image 1


Disclosures: S. Haysen, None; A. Nielsen, None; P. Qvist, None; T. Kragstrup, Aptol Pharma, Pfizer, Bristol-Myers Squibb(BMS), Eli Lilly, Novartis, UCB, AbbVie/Abbott, Gilead.

To cite this abstract in AMA style:

Haysen S, Nielsen A, Qvist P, Kragstrup T. Genomics of JAK-STAT Signaling in Venous Thromboembolism [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/genomics-of-jak-stat-signaling-in-venous-thromboembolism/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/genomics-of-jak-stat-signaling-in-venous-thromboembolism/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology